Sun Pharma an outperformer; target Rs 1050: Kotak

21962 Investors following Sun Pharma. Share this News with them.

0

Like this story, share it with millions of investors on M3

Sun Pharma an outperformer; target Rs 1050: Kotak

Kotak Securities has recommended outperformer rating on Sun Pharmaceuticals with target price of Rs 1050.

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Buy Reliance Industries; target Rs 2005: Citigroup Merrill Lynch neutral on ONGC Buy Hindustan Construction; target Rs 130: Citigroup Buy Bharti Airtel; target Rs 956: ICICI Securities Ipca Labs an outperformer; target Rs 1013: SSKI Sun Pharma BSE | NSE 25/05/12 Are Mutual Funds betting on Sun Pharma?

Kotak Securities has recommended outperformer rating on Sun Pharmaceuticals with target price of Rs 1050.

Kotak Securities report on Sun Pharmaceuticals:

Sun Pharma plans to raise Rs 35 billion (USD 850 million) by issue of equity/convertible bonds. This will imply a 16.5% dilution, assuming an issuance at market price. With a cash-chest of USD 850 million, Sun will likely continue its prowl for under-utilized assets. Thus far, the acquisition strategy seems to have been value accretive.

Clearly with two events (closure of Taro acquisition and fund raising) outstanding, the stock is un-likely to move up in the short-term. However, the long-term growth strategy seems to be getting stronger.

Sun recently announced its intent of acquiring Taro Pharma at an EV of Rs 22.5 billion (not factored into our estimates). Only the deal price of USD 454 million will reduce our FY2008 net profit estimate by 8% (loss of interest income). In CY2005, Taro had sales of USD 298 million sales and net profit of USD 6 million (65% gross margin and 14% operating margin). However numbers have significantly deteriorated in CY2006, with sales of USD 180-200 million and net loss of USD 95-120 million. This will likely be skewed towards non-recurring charges in our opinion. This deal will be negative to EPS for FY2008, and as per the management be accretive in FY2009.

Valuation

We have fine-tuned our model. For FY2008, we estimate revenue growth of 23% and EPS growth of 16% to Rs 43.4. Despite assuming 280bps margin expansion, our EPS growth is constrained by sharp drop in other income. Our EPS will likely drop by another 8%, if we were to assume the fund outflow for the Taro acquisition. For FY2009, we have modeled 21% revenue growth and 25% EPS growth to Rs 54.2.